RUMORED BUZZ ON LINSITINIB CLINICAL TRIALS

The LIDS trial fulfilled its primary endpoint with statistical significance for the 150mg BID dose. Linsitinib In this particular demo validated the security profile noticed from the prior oncology research and importantly demonstrated a favorable security profile on essential adverse situations (AEs) of desire with the IGF-1R target like hearing i